Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo® - GlobeNewswire

Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®  GlobeNewswire

JATENZO® is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult hypogonadal ...



Comments

Popular posts from this blog

Epidemiology and prevention of venous thromboembolism

Deep Vein Thrombosis (DVT): Symptoms, Treatment, & More